BAX Q2 2025 Earnings
Reported Jul 31, 2025 at 7:18 AM ET · SEC Source
Q2 25 EPS
$0.59
MISS 3.12%
Est. $0.61
Q2 25 Revenue
$2.81B
MISS 0.45%
Est. $2.82B
vs S&P Since Q2 25
-20.5%
TRAILING MARKET
BAX -4.5% vs S&P +16.0%
Market Reaction
Did BAX Beat Earnings? Q2 2025 Results
Baxter International delivered a disappointing second quarter, with adjusted EPS of $0.59 missing the Wall Street consensus of $0.61 by 3.28%, as the lingering aftershocks of Hurricane Helene continued to weigh on results. Revenue of $2.81 billion ro… Read more Baxter International delivered a disappointing second quarter, with adjusted EPS of $0.59 missing the Wall Street consensus of $0.61 by 3.28%, as the lingering aftershocks of Hurricane Helene continued to weigh on results. Revenue of $2.81 billion rose 4.3% year over year, but persistent hospital fluid conservation efforts following last year's storm dampened demand in the Medical Products & Therapies segment, which came in flat at $1.32 billion on a reported basis. The company's shares plunged to their lowest level in nearly two decades following the report, a reaction compounded by Baxter's decision to halt infusion pump shipments and trim its full-year outlook. Management now expects full-year 2025 reported sales growth of 6% to 7% and adjusted diluted EPS of $2.42 to $2.52, a range that explicitly accounts for potential downside risks in Medical Products. For Q3, Baxter guided to adjusted EPS of $0.58 to $0.62, offering investors little immediate relief as the company navigates its post-Helene recovery under incoming CEO Andrew Hider, who takes the helm September 3.
Key Takeaways
- • Strength globally for Advanced Surgery and infusion systems products within Infusion Therapies & Technologies
- • Solid global growth for Care & Connectivity Solutions with improvement internationally
- • Drug Compounding strength in Pharmaceuticals segment
- • IV solutions demand softness due to fluid conservation efforts post-Hurricane Helene partially offset Medical Products & Therapies growth
- • Anesthesia sales declined low double digits globally
- • Injectables sales declined 1% due to difficult prior-year comparison from timing of a government order
BAX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
BAX Revenue by Segment
With YoY comparisons, source: SEC Filings
BAX Revenue by Geography
With YoY comparisons, source: SEC Filings
“For the second quarter of 2025, Baxter delivered performance in line with guidance while our employees across the globe continued advancing the company's life-sustaining Mission and building on its vision to redefine healthcare delivery.”
— Brent Shafer, Q2 2025 Earnings Press Release
BAX Earnings Trends
BAX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BAX EPS Trend
Earnings per share: estimate vs actual
BAX Revenue Trend
Quarterly revenue: estimate vs actual
BAX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.31 | $0.36 | +15.90% | $2.70B | +3.27% |
| Q4 25 MISS FY | $0.54 | $0.44 | -17.80% | $2.97B | +5.28% |
| FY Full Year | — | $2.27 | — | $11.24B | — |
| Q3 25 BEAT | $0.60 | $0.69 | +15.40% | $2.84B | -1.47% |
| Q2 25 MISS | $0.61 | $0.59 | -3.12% | $2.81B | -0.45% |